BR112013002587A2 - compostos químicos - Google Patents

compostos químicos

Info

Publication number
BR112013002587A2
BR112013002587A2 BR112013002587A BR112013002587A BR112013002587A2 BR 112013002587 A2 BR112013002587 A2 BR 112013002587A2 BR 112013002587 A BR112013002587 A BR 112013002587A BR 112013002587 A BR112013002587 A BR 112013002587A BR 112013002587 A2 BR112013002587 A2 BR 112013002587A2
Authority
BR
Brazil
Prior art keywords
chemical compounds
compounds
formula
methods
salts
Prior art date
Application number
BR112013002587A
Other languages
English (en)
Inventor
Yang Bin
Peng Bo
Aquila Brian
Carlos Saeh Jamal
Thakur Kumar
Pontz Timothy
Kamhi Victor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112013002587A2 publication Critical patent/BR112013002587A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos químicos. a presente invenção refere-se a compostos da fórmula (i) e/ou fórmula (ia): e a seus sais, composições farmacêuticas, métodos de uso, e métodos para sua preparação. estes compostos inibem atividade de alk cinase, e desta forma podem ser usados para o tratamento de câncer.
BR112013002587A 2010-08-02 2011-08-02 compostos químicos BR112013002587A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36991710P 2010-08-02 2010-08-02
US37205510P 2010-08-09 2010-08-09
US39094410P 2010-10-07 2010-10-07
PCT/GB2011/051465 WO2012017239A2 (en) 2010-08-02 2011-08-02 Chemical compounds

Publications (1)

Publication Number Publication Date
BR112013002587A2 true BR112013002587A2 (pt) 2019-09-24

Family

ID=45527326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002587A BR112013002587A2 (pt) 2010-08-02 2011-08-02 compostos químicos

Country Status (14)

Country Link
US (1) US8461170B2 (pt)
EP (1) EP2601186A2 (pt)
JP (1) JP2013534221A (pt)
KR (1) KR20130096241A (pt)
CN (1) CN103153982A (pt)
AR (1) AR089550A1 (pt)
AU (1) AU2011287386A1 (pt)
BR (1) BR112013002587A2 (pt)
CA (1) CA2805827A1 (pt)
MX (1) MX2013001361A (pt)
RU (1) RU2013109132A (pt)
TW (1) TW201219383A (pt)
UY (1) UY33539A (pt)
WO (1) WO2012017239A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02887B (me) 2011-07-27 2018-04-20 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za tretman raka
CN102899882B (zh) * 2012-11-07 2014-08-06 西南大学 超亲水涤纶织物的磷酸制备方法
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN105085550B (zh) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 一类alk激酶抑制剂及其制备方法
CR20170011A (es) * 2014-06-19 2017-04-04 Ariad Pharma Inc Compuestos de heteroarilo para la inhibición de cinasa
JP6606278B2 (ja) * 2015-08-31 2019-11-13 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド ２−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用
CN106810553B (zh) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
EA039868B1 (ru) * 2017-01-26 2022-03-22 Ханми Фарм. Ко., Лтд. Пиримидиновое соединение и его фармацевтическое применение
US11931536B2 (en) * 2017-07-26 2024-03-19 Dk Medical Technology Co., Ltd. Surface liquefied drug-coated balloon
CA3096790C (en) * 2018-04-09 2024-03-19 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
CN116763792B (zh) * 2023-06-19 2024-03-12 西安国际医学中心医院 Hg-14-10-04在制备治疗食管鳞癌的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
JP2009520785A (ja) 2005-12-23 2009-05-28 アストラゼネカ アクチボラグ 抗菌性のピロロピリジン、ピロロピリミジン、及びピロロアゼピン
AU2007261440A1 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2400619T3 (es) * 2007-06-01 2013-04-11 Glaxosmithkline Llc Inhibidores de imidazopiridina quinasa
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
WO2010049731A1 (en) * 2008-10-29 2010-05-06 Astrazeneca Ab Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2012017239A2 (en) 2012-02-09
WO2012017239A3 (en) 2012-04-05
RU2013109132A (ru) 2014-09-10
AR089550A1 (es) 2014-09-03
KR20130096241A (ko) 2013-08-29
US20120028924A1 (en) 2012-02-02
TW201219383A (en) 2012-05-16
JP2013534221A (ja) 2013-09-02
CN103153982A (zh) 2013-06-12
MX2013001361A (es) 2013-05-17
AU2011287386A1 (en) 2013-03-07
US8461170B2 (en) 2013-06-11
CA2805827A1 (en) 2012-02-09
EP2601186A2 (en) 2013-06-12
UY33539A (es) 2012-02-29

Similar Documents

Publication Publication Date Title
BR112013002587A2 (pt) compostos químicos
BR112013002914A2 (pt) promotores de apoptose de n-acilsulfonamida
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
NI201500167A (es) Compuestos químicos
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112015020941A2 (pt) uso de derivados de pirazolopirimidina para o tratamento de distúrbios relacionados a pi3kdelta
BR112015003859A8 (pt) Compostos de pirazolopirimidina como inibidores de quinase
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BR112016000825A8 (pt) compostos moduladores de sulfonamidas dos canais de sódio, composição farmacêutica, e uso dos mesmos
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112015017331A2 (pt) compostos químicos
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
BR112014022214A2 (pt) fenólicos antibacterianos
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
TR201902057T4 (tr) Tetrasiklin bileşikleri.
BR112012024586A2 (pt) compostos de purina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.